摘要:
The present invention relates to compounds of formula (IA), (IB) and (IC): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要:
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要:
The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要:
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes
摘要:
The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要:
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要:
Disclosed herein are several organic compounds having electron-transporting and/or hole-blocking performance and their preparation method and use and the OLEDs comprising the organic compound. The organic compounds exhibit high ionization potential (IP), electron affinity (Ea), glass transition temperature (Tg) and high electron mobility, and are a kind of good electron-transporting material with good hole-blocking ability. The devices comprising these compounds as one of the emitting layer, electron-transporting layer (ETL) and hole-blocking layer (HBL) show improved efficiency and better color purity.
摘要:
A HRPD network access authentication method based on CAVE algorithm is provided. An AT (Access Terminal) generates a random number “RAND” necessary for a calculation of an AUTH1 by using a “Random text” included in the CHAP Challenge message. A UIM (User Identity Module) card works out the AUTH1 by using the random number “RAND” and an SSD_A (Shared Secret Data A) in the UIM card. The AT carries the AUTH1 in a Result field of the CHAP Response message. An AN-AAA (Access Network-Authentication, Authorization, and Accounting) generates the random number “RAND” necessary for the calculation of an AUTH2 by using a “Random text” included in a Radius Access Request message. The AN-AAA works out the AUTH2 by using the random number “RAND”. The two results AUTH1 and AUTH2 are compared. If the results are the same, the authentication on the AT passes. Otherwise, AT access is rejected.